Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25351450 | 0.98 | LRRK2 (0.40) | LRRK2HDAC6HDAC1ROCK2PIM1 | |
| SCHEMBL25349409 | 0.91 | LRRK2 (0.41) | LRRK2HDAC6HDAC1 | |
| SCHEMBL30460258 | 0.91 | HDAC6 (0.48) | HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL24216144 | 0.91 | HDAC6 (0.48) | HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL30409874 | 0.89 | HDAC6 (0.48) | HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL24215810 | 0.89 | HDAC6 (0.48) | HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL30410137 | 0.87 | HDAC6 (0.38) | HDAC6 | |
| SCHEMBL24216546 | 0.87 | HDAC6 (0.38) | HDAC6 | |
| SCHEMBL25348318 | 0.86 | HDAC6 (0.39) | HDAC6HDAC1 | |
| SCHEMBL30409824 | 0.86 | HDAC6 (0.39) | HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | LRRK2 1788/4885HDAC6 1/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.